Lion Point Capital’s BridgeBio Pharma BBIO Stock Holding History

Lion Point Capital’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$372K	Hold	5,000	–	–	1.78%	21
2026 Q1	$371K	Hold	5,000	–	–	2.22%	20
2025 Q4	$382K	Sell	5,000 -8,300	-62%	-$545K	1.98%	21
2025 Q3	$691K	Sell	13,300 -12,700	-49%	-$619K	3.92%	13
2025 Q2	$1.12M	Hold	26,000	–	–	7.62%	4
2025 Q1	$899K	Sell	26,000 -14,300	-35%	-$482K	5.73%	6
2024 Q4	$1.11M	Sell	40,300 -8,700	-18%	-$225K	5.79%	6
2024 Q3	$1.25M	Hold	49,000	–	–	2.78%	9
2024 Q2	$1.24M	Buy	+49,000	New	+$1.34M	2.26%	11

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Lion Point Capital's BBIO Position: Q2 2026 in Review

Lion Point Capital held its BridgeBio Pharma (BBIO) position steady in Q2 2026 at 5,000 shares worth $372K. The position accounts for 1.78% of the portfolio, ranked #21.

Lion Point Capital first reported a position in BBIO in Q2 2024 and has held it in 9 quarters since. The position peaked at $1.25M in Q3 2024. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Lion Point Capital held 5,000 shares of BridgeBio Pharma worth $372K as of Q2 2026.
Lion Point Capital left its BridgeBio Pharma share count unchanged in Q2 2026.
BridgeBio Pharma made up 1.78% of Lion Point Capital's portfolio in Q2 2026, its #21 holding.
Lion Point Capital first reported a position in BridgeBio Pharma in Q2 2024 and has held it in 9 quarters since.
Lion Point Capital's BridgeBio Pharma position peaked at $1.25M in Q3 2024.
474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Lion Point Capital's 13F filing for Q2 2026, filed 14 Aug 2026.